- Previous Close
0.2185 - Open
0.2035 - Bid 0.2090 x --
- Ask 0.2500 x --
- Day's Range
0.2035 - 0.2035 - 52 Week Range
0.1012 - 0.6510 - Volume
1,000 - Avg. Volume
0 - Market Cap (intraday)
19.59M - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1500 - Earnings Date Dec 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the United States of America. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. Biovica International AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.
www.biovica.comRecent News: 9II.F
View More
Performance Overview: 9II.F
Trailing total returns as of 9/24/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9II.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9II.F
View MoreValuation Measures
Market Cap
21.03M
Enterprise Value
15.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.32
Price/Book (mrq)
2.51
Enterprise Value/Revenue
24.96
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.99%
Return on Equity (ttm)
-117.91%
Revenue (ttm)
7.24M
Net Income Avi to Common (ttm)
-115.45M
Diluted EPS (ttm)
-0.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
65.21M
Total Debt/Equity (mrq)
7.77%
Levered Free Cash Flow (ttm)
-63.31M
Company Insights: 9II.F
9II.F does not have Company Insights